放射性碘治疗转移性甲状腺滤泡癌后发生的急性髓系白血病。
Acute Myeloid Leukemia following Radioactive Iodine Therapy for Metastatic Follicular Carcinoma of the Thyroid.
作者信息
Bishnoi Komal, Emerson Ralph, Parida Girish Kumar, Acharya Prapti, Padhi Somanath, Agrawal Kanhaiyalal
机构信息
Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
出版信息
Indian J Nucl Med. 2023 Jan-Mar;38(1):56-58. doi: 10.4103/ijnm.ijnm_133_22. Epub 2023 Feb 24.
Radioactive iodine (RAI) therapy is widely used and has an important role in the management of hyperthyroidism and thyroid malignancies. The development of acute or chronic leukemia is a very rare complication of RAI therapy. We report a case of metastatic Follicular thyroid cancer (FTC) who underwent total thyroidectomy followed by treatment with a cumulative dose of 1600 mCi of RAI (for 4 years) and by palliative radiotherapy for L4 spinal metastasis, later on, developed acute myeloid leukemia. Thus, all patients with thyroid carcinoma treated with RAI should undergo periodic hematological examinations irrespective of RAI dose.
放射性碘（RAI）治疗被广泛应用，在甲状腺功能亢进症和甲状腺恶性肿瘤的治疗中发挥着重要作用。急性或慢性白血病的发生是RAI治疗极为罕见的并发症。我们报告一例转移性滤泡性甲状腺癌（FTC）患者，该患者接受了全甲状腺切除术，随后接受了累积剂量为1600毫居里的RAI治疗（为期4年），并因L4椎体转移接受了姑息性放疗，后来发展为急性髓系白血病。因此，所有接受RAI治疗的甲状腺癌患者，无论RAI剂量如何，均应定期进行血液学检查。
Zotero 插件